Press Releases March 25, 2026 06:39 PM

Arrowmark Financial Corp. Releases Month End Estimated Net Asset Value as of February 2026

ArrowMark Financial Reports Estimated Net Asset Value for February 2026

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
BANX

ArrowMark Financial Corp. announced its estimated and unaudited Net Asset Value (NAV) as of February 28, 2026, at $21.18 per share. The firm is a closed-end fund listed on NASDAQ focusing on income through investments primarily in regulatory capital securities of financial institutions. The announcement includes a reminder of associated investment risks and encourages investors to review detailed regulatory filings.

Arrowmark Financial Corp. Releases Month End Estimated Net Asset Value as of February 2026
BANX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Estimated NAV as of February 28, 2026, is $21.18 per share.
  • ArrowMark Financial is a non-diversified, closed-end fund investing mainly in regulatory capital securities of financial institutions.
  • The company highlights various investment and market risks inherent in its portfolio, including interest rate, credit, liquidity, and leverage risks.

DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- ArrowMark Financial Corp., (NASDAQ: BANX) ("ArrowMark Financial"), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of February 28, 2026, was $21.18.

This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended February 28, 2026.

About ArrowMark Financial Corp.
ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact Destra at 877.855.3434 or by email at BANX@destracapital.com.

Disclaimer and Risk Factors:
There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial's investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Company with the SEC are accessible on the SEC's website at www.sec.gov and on the BANX’s website at ir.arrowmarkfinancialcorp.com.

Contact:
BANX@destracapital.com


Risks

  • Investment and market risks could affect performance due to exposure to banking and financial sectors.
  • Leverage and liquidity risks may affect the fund’s ability to meet obligations or deploy capital effectively.
  • Market disruptions and trading at discounts or premiums to NAV could cause share price volatility.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026